Chemical vs Electrical Cardioversion for Emergency Department Patients With Acute Atrial Fibrillation

PHASE3CompletedINTERVENTIONAL
Enrollment

86

Participants

Timeline

Start Date

November 30, 2013

Primary Completion Date

March 31, 2015

Study Completion Date

April 30, 2015

Conditions
Atrial Fibrillation
Interventions
DRUG

Electrical-first

Patients will be placed on cardiopulmonary blood pressure monitoring, and sedated with propofol 0.5 - 1.0 mg / kg. Once a Ramsay Sedation Scale score of 5 or greater is reached, the physician will attempt synchronized electrical cardioversion with 100 J, 200 J, 200 J. If the patient converts to normal sinus rhythm by the third shock, the physician may discharge the patient. If atrial fibrillation is maintained, the patient will receive intravenous procainamide 17 mg / kg over 30 minutes. If the rhythm has changed from atrial fibrillation to normal sinus within one hour, the attending physician may discharge the patient, otherwise a cardiologist will be consulted.

DRUG

Chemical-first

Patients will be placed on cardiopulmonary blood pressure monitoring, and will receive intravenous procainamide 17 mg / kg over 30 minutes. If the rhythm has changed from atrial fibrillation to normal sinus within one hour, the attending physician may discharge the patient. If the rhythm has not changed, then the patient will be continue to have cardiopulmonary monitoring, but also be attended by a respiratory therapist. The patient will be sedated with propofol 0.5 - 1.0 mg / kg. Once a Ramsay Sedation Scale score of 5 or greater is reached, the physician will attempt synchronized electrical cardioversion with 100 J, 200 J, 200 J. If the patient converts to normal sinus rhythm by the third shock, the physician may discharge the patient, otherwise a cardiologist will be consulted.

Trial Locations (1)

V6Z 1Y6

St Paul's Hospital, Vancouver

All Listed Sponsors
lead

University of British Columbia

OTHER

NCT01994070 - Chemical vs Electrical Cardioversion for Emergency Department Patients With Acute Atrial Fibrillation | Biotech Hunter | Biotech Hunter